Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8WYP3
UPID:
RIN2_HUMAN
Alternative names:
Ras association domain family 4; Ras inhibitor JC265; Ras interaction/interference protein 2
Alternative UPACC:
Q8WYP3; Q00425; Q5TFT8; Q9BQL3; Q9H071
Background:
Ras and Rab interactor 2, alternatively known as Ras association domain family 4, Ras inhibitor JC265, and Ras interaction/interference protein 2, plays a pivotal role in the endocytic pathway. It functions as a Ras effector protein, potentially acting as both an upstream activator and downstream effector for RAB5B. Its activity includes functioning as a guanine nucleotide exchange (GEF) for RAB5B, essential for activating RAB5 proteins by exchanging bound GDP for free GTP.
Therapeutic significance:
The protein's involvement in MACS syndrome, a complex disorder of elastic tissue, underscores its therapeutic significance. Understanding the role of Ras and Rab interactor 2 could open doors to potential therapeutic strategies for treating or managing MACS syndrome and its life-threatening complications.